MBX Biosciences' canvuparatide meets Phase 2 primary endpoint: 63% responder rate, p=0.042, 79% at 6 months OLE

MBX Biosciences, Inc.

Primary composite endpoint met: 63% (30/48) of canvuparatide patients vs 31% (5/16) placebo at Week 12 (p=0.042).
Open-label extension: 79% (44/56) achieved responder status at 6 months, including placebo crossovers.
Safety: well-tolerated, no treatment-related SAEs or discontinuations; injection site reactions 19% vs 13% placebo.
Company plans to initiate Phase 3 trial of once-weekly canvuparatide in 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.